Download this file

# pmid doi year title Hugo_Symbol
1 33297669 10.3324/haematol.2020.267294 2022 Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. CD58
2 34560683 10.1097/PAS.0000000000001813 2022 A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. CD58
3 35317330 10.14740/wjon1436 2022 Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis. CD58
4 35491222 10.11406/rinketsu.63.313 2022 [Epigenetic modification as a therapeutic approach for B-cell lymphoma]. CD58
5 35622145 10.1007/s00428-022-03348-x 2022 CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma. CD58
6 35881486 10.1172/JCI159402 2022 Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. CD58
7 33340851 10.1016/j.leukres.2020.106491 2021 Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia. CD58
8 33479306 10.1038/s41598-020-80376-0 2021 Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. CD58
9 33544565 10.1097/PAS.0000000000001658 2021 Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. CD58
10 33777778 10.3389/fonc.2021.628807 2021 Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. CD58
11 34339834 10.1016/j.critrevonc.2021.103430 2021 Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review. CD58
12 34937829 10.3960/jslrt.21007 2021 Tumor microenvironment of adult T-cell leukemia/lymphoma. CD58
13 31254446 10.1002/cyto.b.21834 2020 Immunophenotypic Characterization and Purification of Neoplastic Cells from Lymph Nodes Involved by T-Cell/Histiocyte-rich Large B-cell Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting. CD58
14 31962268 10.1016/j.molimm.2020.01.006 2020 EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. CD58
15 32068791 10.1093/ajcp/aqaa007 2020 Improved Recognition of Hematogones From Precursor B-Lymphoblastic Leukemia by a Single Tube Flow Cytometric Analysis. CD58
16 32322878 10.1093/ibd/izaa065 2020 Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. CD58
17 32589698 10.1182/blood.2020005546 2020 Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58. CD58
18 31292115 10.1182/blood.2019001126 2019 Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. CD58
19 31597848 10.11406/rinketsu.60.1229 2019 [The immune microenvironment in malignant lymphoma]. CD58
20 31934533 10.1155/2019/8586354 2019 Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis. CD58
21 29564225 10.3389/fonc.2018.00054 2018 Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. CD58
22 29857068 10.1016/j.jid.2018.04.038 2018 Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. CD58
23 29902581 10.1016/j.meegid.2018.06.010 2018 Low responsiveness to a hepatitis B virus vaccine in a Chinese population lacks association with ITGAL, CD58, TNFSF15, CCL15, TGFB3, and BCL6 gene variants. CD58
24 30093402 10.1182/blood-2018-03-838524 2018 Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with <i>DUSP22</i> rearrangements. CD58
25 27998726 10.1016/j.ajpath.2016.10.007 2017 Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. CD58
26 28446317 10.7534/j.issn.1009-2137.2017.02.051 2017 [Research Progress on Relationship between CD58 Molecule and ALL and Lymphoma -Review]. CD58
27 28627735 10.1111/cas.13303 2017 Genetic alterations in adult T-cell leukemia/lymphoma. CD58
28 28694326 10.1182/blood-2017-02-768234 2017 Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). CD58
29 27069035 10.1093/labmed/lmw009 2016 Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall. CD58
30 27276707 10.18632/oncotarget.9793 2016 Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. CD58
31 27389058 10.1038/leu.2016.161 2016 Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. CD58
32 27467287 10.1038/gene.2016.30 2016 CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse. CD58
33 27825110 10.18632/oncotarget.13065 2016 Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. CD58
34 25582824 10.1038/mt.2015.4 2015 Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. CD58
35 25800755 10.1200/JCO.2014.57.7080 2015 Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. CD58
36 25991819 10.1158/1078-0432.CCR-14-2116 2015 Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. CD58
37 26106001 10.3960/jslrt.55.13 2015 Mutation Analysis for TP53 in Chronic-Type Adult T-Cell Leukemia/Lymphoma. CD58
38 26194173 10.1002/gcc.22276 2015 Alterations of the CD58 gene in classical Hodgkin lymphoma. CD58
39 26550829 10.1159/000431058 2015 Molecular Pathology of Adult T-Cell Leukemia/Lymphoma. CD58
40 24413734 10.1038/ng.2873 2014 Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. CD58
41 25320005 10.1158/0008-5472.CAN-14-0643 2014 Molecular characterization of chronic-type adult T-cell leukemia/lymphoma. CD58
42 22585868 10.1158/2159-8290.CD-RW2011-64 2012 Gene inactivation promotes immune escape in DLBCL. CD58
43 22713438 10.1177/120347541201600305 2012 Biologic therapy in psoriasis: perspectives on associated risks and patient management. CD58
44 20634374 10.1182/blood-2008-01-130252 2011 Human CD14hi monocytes and myeloid dendritic cells provide a cell contact-dependent costimulatory signal for early CD40 ligand expression. CD58
45 21669033 10.3727/096368911X580536 2011 Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. CD58
46 22137796 10.1016/j.ccr.2011.11.006 2011 Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. CD58
47 18412874 10.1111/j.1365-4632.2008.03470.x 2008 Combining systemic retinoids with biologic agents for moderate to severe psoriasis. CD58
48 18809238 10.1016/j.exphem.2008.07.003 2008 Costimulation molecule expression and subset distribution of blood dendritic cells in normal children and newly diagnosed pediatric leukemia and lymphoma patients. CD58
49 17349557 10.1016/j.sder.2006.12.002 2007 Complications and adverse reactions in the use of newer biologic agents. CD58
50 15737916 10.1016/j.meegid.2004.08.006 2005 Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders. CD58
51 15360006 10.1080/10428190310001643358 2004 Defective immune function of primary effusion lymphoma cells is associated with distinct KSHV gene expression profiles. CD58
52 12671023 10.1093/jnci/95.7.548 2003 Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. CD58
53 12915579 10.1128/jvi.77.17.9669-9684.2003 2003 Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. CD58
54 12008089 10.1016/s0145-2126(01)00198-9 2002 Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases. CD58
55 12215016 10.1007/BF02982580 2002 Establishment of a primary effusion lymphoma cell line (RM-P1) and in vivo growth system using SCID mice. CD58
56 11389007 10.1182/blood.v97.12.3713 2001 The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. CD58
57 10664622 10.1309/BFH5-NCNP-DK3J-DQBH 2000 Angiodestruction and tissue necrosis of skin-involving CD56+ NK/T-cell lymphoma are influenced by expression of cell adhesion molecules and cytotoxic granule and apoptosis-related proteins. CD58
58 10089910 10.1016/s0301-472x(98)00059-9 1999 Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. CD58
59 10482995 10.1038/sj.leu.2401517 1999 Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkin's lymphoma. CD58
60 10791904 10.1089/152581699319984 1999 Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells. CD58
61 9894758 NA 1998 Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. CD58
62 9083889 10.1023/a:1027374331094 1997 A novel human monoclonal antibody rapidly induces homotypic cell aggregation and promotes antibody-secreting activity by human B lymphoblastoid cell line IM-9. CD58
63 9498712 10.3109/10428199709058339 1997 Relationships between susceptibility to LAK cell-mediated lysis, conjugate formation and expression of adhesion molecules in B-cell derived non-Hodgkin's lymphomas. CD58
64 11725077 10.1007/BF02253573 1996 Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. ii. from cytokines to cell lineage. CD58
65 8806537 10.1006/viro.1996.0452 1996 Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. CD58
66 8917708 10.1007/BF00192429 1996 Lack of adhesion molecules in testicular diffuse centroblastic and immunoblastic B cell lymphomas as a contributory factor in malignant behaviour. CD58
67 11725067 10.1007/BF02255217 1995 Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas. CD58
68 7490134 NA 1995 Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line. CD58
69 7866283 10.3109/10428199409049732 1994 Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells. CD58
70 7681932 10.1016/0161-5890(93)90112-o 1993 Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines. CD58
71 8214003 NA 1993 Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. CD58
72 8344715 10.1016/0165-2478(93)90066-b 1993 The effect of IL-4 on the phenotype of a human B-cell lymphoma line (Farage) lacking immunoglobulin expression. CD58
73 1282031 10.1093/intimm/4.11.1283 1992 Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells. CD58
74 1317364 10.1002/ijc.2910510319 1992 Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt's lymphoma cells. CD58
75 1372880 10.1002/ijc.2910500605 1992 Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells. CD58
76 1378014 10.1002/eji.1830220712 1992 Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition. CD58
77 1381563 NA 1992 Adhesion receptor profile of thymic B-cell lymphoma. CD58
78 1717480 10.1083/jcb.115.1.245 1991 Influence of receptor lateral mobility on adhesion strengthening between membranes containing LFA-3 and CD2. CD58
79 1721040 NA 1991 Expression of the CDw75 (beta-galactoside alpha 2,6-sialyltransferase) antigen on normal blood cells and in B-cell chronic lymphocytic leukaemia. CD58
80 1722139 10.1007/BF01741347 1991 Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes. CD58
81 27463481 10.3109/10428199109103380 1991 Expression of CD11a (LFA-1) on B-chronic Lymphocytic Leukemia and Lymphoma Cells: Correlation with Cell Surface Immunoglobulin Intensity and CD58 (LFA-3) Expression. CD58
82 1691936 NA 1990 Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA-3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus. CD58
83 1698730 10.1002/ijc.2910460418 1990 Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). CD58
84 2572856 10.1016/s0140-6736(89)91498-0 1989 Leucocyte adhesion to cells in immune and inflammatory responses. CD58